BCL2 and central nervous system cancer: Of note the treatment of U251 glioma cell line with SR141716 is able to reduce the expression levels of the cell cycle regulator Cyclin D1 (Fig. 1D), of the anti-apoptotic Bcl-2, Bcl-XL (Supplementary Fig. 1) and the TGF-β1 production (Fig. 6A), all canonical targets of a deregulated STAT3 transcriptional activity in the process of carcinogenesis and tumor survival [34].